Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ESPR - Esperion Therapeutics, Inc. Latest News | Finranks

Home

ESPR

(ESPR)

NGM – Real Time Price. Currency in USD

2.74

-0.11 (-3.86%)

At close: Mar 27, 2026, 4:00 PM EDT

2.72

-0.02 (-0.73%)

After-hours: Mar 27, 2026, 5:54 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M

ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M

Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Videos

No Data

There is no data to display

Press releases

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ANN ARBOR, Mich. & HENDERSON, Nev.--(BUSINESS WIRE)-- #CHF--Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia.